The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer.

BACKGROUND: Individuals with cancer experience loss of function and disability due to disease and cancer-related treatments. Physical fitness and frailty influence treatment plans and may predict cancer outcomes. Outcome measures currently used may not provide sufficiently comprehensive assessment of physical performance. OBJECTIVE: The objectives of this study are to: (1) describe the development of a functional measure, the Bellarmine Norton Assessment Tool (BNAT), for individuals with cancer; and (2) assess the relationship between the BNAT and the Eastern Cooperative Oncology Group (ECOG) Performance Status, a commonly used classification system by oncologists. DESIGN: This was a prospective cohort correlation study. METHODS: The BNAT encompasses 1 self-reported physical activity question and 4 objective tests: 2-Minute Step Test, 30-Second Sit to Stand, Timed Arm Curl, and Timed Up and Go. The BNAT score and its components were compared with ECOG Performance Status scores assigned by oncologists and analyzed for correlation and agreement. RESULTS: A total of 103 male and female individuals (ages 33-87 years) with various cancer diagnoses participated. The mean (SD) ECOG Performance Status score was 0.95 (0.87), range 0 to 3, and the mean BNAT score was 14.9 (4.3), range 5 to 24. Spearman agreement association of BNAT and ECOG Performance Status scores revealed a significant moderate negative relationship (r = -0.568). LIMITATIONS: The BNAT was compared with the ECOG Performance Status, a commonly used but subjective measure. Additionally, a common data set was used for both deriving and evaluating the BNAT performance scale. CONCLUSIONS: There was a moderate negative linear relationship of BNAT to ECOG Performance Status scores across all participants. Utilization of the BNAT may reflect overall physical performance and provide comprehensive and meaningful detail to influence therapeutic decisions.

Variability of master gutta-percha cones.

The common technique to hermetically fill prepared root canals involves the use of "standardised" gutta-percha cones that are selected to fit the apical portion of the prepared canal space. These gutta-percha cones are manufactured to conform to a standard size and taper which should correspond to the size and taper of standard root canal instruments. Clinical observation of commercially available gutta-percha cones seemed to indicate that there is wide variation in the diameter and taper of "standardised" gutta-percha cones within the size range 25-35. The present study was undertaken to determine how closely current commercially available gutta-percha cones sizes 25, 30 and 35 conformed to the current ISO standard, and was initiated by the above clinical observation. It was not the purpose of this study to compare the results from different brands or manufacturers, but rather to establish whether commercially available gutta-percha cones collectively conformed to expected standardised sizes. One phial of cones for each of the sizes 25, 30 and 35 of eight different brands was selected for examination. The diameter of each of ten cones for each size from each brand was measured at two points, at 1 mm and at 6 mm from the tip of the cone. The results obtained for each size and each brand were tabulated and compared with ISO 6877:1995 for dental root canal obturating cones. This study demonstrated wide variability for cones from all brands, for all sizes, when individual cones of the same size were compared. While collectively the arithmetic means showed a closer correlation to the ISO Standard, irrespective of the brand size of the cone, or whether the cone was measured at 1 mm or 6 mm, many individual cones showed a great variation from the ideal. The need for less variability is discussed. It is concluded that ISO standard 6877:1995 is inappropriate- and allows for too much variation in the size of "standardised" gutta-percha cones.

A validated bioanalytical method in mouse, rat, rabbit and human plasma for the quantification of one of the steroid glycosides found in Hoodia gordonii extract.

Hoodia gordonii extract contains steroid glycosides, fatty acids, plant sterols and polar organic material. Certain steroid glycosides show appetite suppressant activities following oral ingestion. This study describes the validation of a bioanalytical method for the quantification of one of the steroid glycosides, H.g.-12 (≈ 10% (w/w) of the extract), in mouse, rat, rabbit and human plasma. The method utilises a liquid-liquid extraction with methyl-tert-butyl ether followed by chromatographic separation on a 2.1 × 50 mm C(18) Genesis high performance liquid chromatography (HPLC) column and detection on a triple quadrupole mass spectrometer. Detection of H.g.-12 and its stable isotope internal standards is performed using positive TurboIonspray™ ionisation in multiple reaction monitoring mode. The validation procedure demonstrated assay sensitivity, linearity, accuracy, precision and selectivity over the calibration range of 0.5-150 ng/mL in human plasma (500 µL sample volume), 1.0-100 ng/mL in rat and rabbit plasma (150 µL sample volume) and 1.0-250 ng/mL in mouse plasma (150 µL sample volume) with good recoveries (≥ 77%). H.g.-12 was stable in plasma for ≥ 6 months at -20°C, for up to 4h at ambient temperature (ca22°C) and after 3 freeze-thaw cycles. Plasma extracts were stable for up to 24h at ambient temperature.